Suppr超能文献

在使用 Zalmtocecabtagene Autoleucel 进行双靶向 CD20-CD19 非冷冻 CAR-T 细胞治疗后,类风湿关节炎患者伴弥漫性大 B 细胞淋巴瘤实现持续无药物缓解。

Sustained drug-free remission in rheumatoid arthritis associated with diffuse large B-cell lymphoma following tandem CD20-CD19-directed non-cryopreserved CAR-T cell therapy using zamtocabtagene autoleucel.

机构信息

Miltenyi Biomedicine GmbH, Bergisch Gladbach, Nordrhein-Westfalen, Germany

Department of Hematology, Central Hospital of Southern Pest, National Institute of Hematology and Infectious Diseases, Budapest, Hungary.

出版信息

RMD Open. 2024 Oct 23;10(4):e004727. doi: 10.1136/rmdopen-2024-004727.

Abstract

We report the case of long-term persisting rheumatoid arthritis (RA), treated with CD20-CD19 CAR-T when it became associated with diffuse large B cell lymphoma (DLBCL), resulting in a sustained drug-free remission of the preceding RA, as well as of the subsequent DLBCL that formed the indication of the CAR-T therapy using zamtocabtagene autoleucel, with a 1-year follow-up. According to our best knowledge, this is the first published clinical case report of long-term persisting RA treated with CAR-T cell therapy.

摘要

我们报告了一例长期持续性类风湿关节炎(RA)的病例,在其并发弥漫性大 B 细胞淋巴瘤(DLBCL)时,使用 CD20-CD19 CAR-T 进行治疗,导致先前的 RA 和随后形成 CAR-T 治疗适应证的 DLBCL 均获得了持续无药物缓解,且随访时间达 1 年。据我们所知,这是首例使用嵌合抗原受体 T 细胞(CAR-T)疗法治疗长期持续性 RA 的临床病例报告。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b76/11499799/80e87263ccc9/rmdopen-10-4-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验